Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.

Drug manufacturers saw their stock prices fall on Friday after vaccine skeptic Robert F. Kennedy Jr. was announced as Trump's ...

Graeme Sloan / Bloomberg via Getty Images Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.

The Gaithersburg biotech is preparing to turn over sales activity for its only product to its commercial partner. Novavax Inc. has made a smaller splash in the U.S. Covid-19 vaccine market than it ...

Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a ...

Novavax, Inc. (NASDAQ:NVAX ... the potential for Matrix-M to improve the activity of existing vaccines as in the case of ...

Novavax, Inc., based in Gaithersburg, Maryland, is a global biotechnology company focused on developing and commercializing innovative protein-based vaccines to combat serious infectious diseases, ...

In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...

On 1, Novavax, Inc. (NASDAQ:NVAX) and the U.K. Health Security Agency, representing the U.K. Secretary of State for Health ...

(Reuters) -Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to French drugmaker Sanofi.

On Monday, the FDA said the company could continue testing its combination COVID-19-flu and standalone flu vaccines. Novavax (NVAX) shares dropped Tuesday morning after the company slashed its ...